10. ACQUISITION (Details)		3 Months Ended	9 Months Ended
	Nov. 23, 2015 USD ($) employee patent	Dec. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Mar. 31, 2016 USD ($)
Acquisition disclosure
Cash paid for acquisition				$ 4,359,000
Amount of payment held in escrow	$ 2,500,000
Assets acquired and liabilities assumed
Goodwill		$ 7,978,000	$ 7,978,000		$ 8,030,000
Other assets
Acquisition disclosure
Amount of payment held in escrow		1,750,000	1,750,000
Prepaid expenses and other current assets
Acquisition disclosure
Amount of payment held in escrow		750,000	750,000
MikaMonu
Acquisition disclosure
Number of former shareholders receiving retention payments | employee	3
Cash paid for acquisition	$ 4,400,000
Contingent consideration, acquisition date fair value	2,500,000
Amount of payment held in escrow	$ 484,000
Term of additional contingent payments	4 years
Discount rate (as a percent)	14.80%
Contingent consideration liability	$ 5,800,000
Change in contingent consideration liability		41,000	121,000
Assets acquired and liabilities assumed
Cash and cash equivalents	1,000
Other receivables	54,000
Property and equipment, net	10,000
Intangible assets	3,500,000
Goodwill	8,030,000	(52,000)	(52,000)
Total assets acquired	11,595,000
Accrued expenses	(10,000)
Net deferred tax liability	(821,000)
Total liabilities assumed	(831,000)
Fair value of net assets acquired	10,764,000
MikaMonu | Patents
Assets acquired and liabilities assumed
Intangible assets	$ 3,500,000
Useful life	15 years
MikaMonu | Other accrued expenses
Acquisition disclosure
Contingent consideration liability		4,900,000	4,900,000		$ 5,900,000
MikaMonu | Accrued expenses and other liabilities
Acquisition disclosure
Contingent consideration liability		1,100,000	1,100,000
MikaMonu | United States
Acquisition disclosure
Number of patents held | patent	12
MikaMonu | Continued employment of key employees
Acquisition disclosure
Contingent consideration		1,300,000	1,300,000
MikaMonu | Continued employment of Dr. Avidan Akerib
Acquisition disclosure
Contingent consideration	$ 1,200,000
MikaMonu | Product development milestones and revenue targets
Acquisition disclosure
Term of additional contingent payments	10 years
MikaMonu | Product development milestones and revenue targets | Maximum
Acquisition disclosure
Contingent consideration		$ 38,800,000	$ 38,800,000
MikaMonu | Product development milestones to be achieved by December 31, 2017
Acquisition disclosure
Contingent consideration	$ 750,000
MikaMonu | Revenue milestones to be achieved by January, 1 2021
Acquisition disclosure
Contingent consideration	2,750,000
MikaMonu | Revenue milestones to be achieved by January, 1 2022
Acquisition disclosure
Contingent consideration	4,000,000
MikaMonu | Quarterly payments based on net revenue | Maximum
Acquisition disclosure
Contingent consideration	$ 30,000,000
Contingent consideration, percent of net revenue	5.00%